Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples